Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
January 16, 2007
Pricing matrix model: dealing with uncertainty
Mark J C Nuijten
Pharmacoeconomics
|
August 6, 2004
Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations
Mark J C Nuijten
Pharmacoeconomics
|
September 19, 2002
Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques
Mark J C Nuijten, Frans Rutten
Pharmacoeconomics
|
September 10, 2003
The incorporation of potential confounding variables in Markov models
Mark J C Nuijten, Frans Rutten
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
September 29, 2004
Pricing of pharmaceuticals. Assessing the pricing potential by a pricing matrix model
Mark J C Nuijten, Joszef Kosa
Nature Reviews. Clinical Oncology
|
August 15, 2018
Economic comments on proposal for a novel cancer drug pricing model
Mark J C Nuijten, Jan Vis
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 5, 2002
Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis
Mark J C Nuijten, John Hutton
Frontiers in Pharmacology
|
June 30, 2011
Cost-utility analysis: current methodological issues and future perspectives
Mark J C Nuijten, Dominique J Dubois
Pharmacoeconomics
|
December 29, 2006
Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis
Mark J C Nuijten, Wolfgang Wittenberg, Maximilian Lebmeier
Clinical Drug Investigation
|
May 30, 2007
Economic evaluation of tramadol/paracetamol combination tablets for osteoarthritis pain in the Netherlands
Hiltrud Liedgens, Mark J C Nuijten, Barbara Poulsen Nautrup
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
January 16, 2007
Pricing matrix model: dealing with uncertainty
Mark J C Nuijten
Pharmacoeconomics
|
August 6, 2004
Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations
Mark J C Nuijten
Pharmacoeconomics
|
September 19, 2002
Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques
Mark J C Nuijten, Frans Rutten
Pharmacoeconomics
|
September 10, 2003
The incorporation of potential confounding variables in Markov models
Mark J C Nuijten, Frans Rutten
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
September 29, 2004
Pricing of pharmaceuticals. Assessing the pricing potential by a pricing matrix model
Mark J C Nuijten, Joszef Kosa
Nature Reviews. Clinical Oncology
|
August 15, 2018
Economic comments on proposal for a novel cancer drug pricing model
Mark J C Nuijten, Jan Vis
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 5, 2002
Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis
Mark J C Nuijten, John Hutton
Frontiers in Pharmacology
|
June 30, 2011
Cost-utility analysis: current methodological issues and future perspectives
Mark J C Nuijten, Dominique J Dubois
Pharmacoeconomics
|
December 29, 2006
Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis
Mark J C Nuijten, Wolfgang Wittenberg, Maximilian Lebmeier
Clinical Drug Investigation
|
May 30, 2007
Economic evaluation of tramadol/paracetamol combination tablets for osteoarthritis pain in the Netherlands
Hiltrud Liedgens, Mark J C Nuijten, Barbara Poulsen Nautrup
Page
of 3